All lobbying filings
Orchard Therapeutics North America
Orchard Therapeutics North America filed a Q2 report for Orchard Therapeutics North America on July 17, 2026.
Lobbying for Orchard Therapeutics North America · Health
Filing · LD-2 quarterly report
Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 17, 2026
Expenses
$190,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
Massachusetts
Government bodies contacted
4
Lobbying activity
2
FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD)
S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs